Xiong Dejun, Li Zhao, Zuo Ling, Ge Juan, Gu Yuhan, Zhang Erhao, Zhou Xiaorong, Yu Guiping, Sang Mengmeng
Department of Immunology, School of Medicine, Nantong University, Nantong 226019, China.
Department of Respiratory Medicine, Affiliated Nantong Hospital of Shanghai University, Nantong 226011, China.
Genes (Basel). 2024 Nov 28;15(12):1538. doi: 10.3390/genes15121538.
(Iron-Sulfur Cluster Assembly 1) is involved in the assembly of iron-sulfur (Fe-S) clusters, which are vital for electron transport and enzyme activity. Some studies suggest the potential involvement of in tumor progression through interactions with ferroptosis-related genes (FRGs) and the tumor immune microenvironment (TME). However, there has been no systematic analysis of its role in FRGs and the TME or its predictive value for prognosis and immunotherapy response across different cancer types.
In this study, we analyzed the expression and prognosis of RNA, CNV, methylation, and protein in multiple tumor tissues via data from the TCGA and CPTAC databases and clinical information. We conducted a comprehensive analysis of the correlations between and FRGs, immune-related genes (including immune regulatory genes and immune checkpoint genes), immune cell infiltration, immune infiltration scores, tumor stemness, and genomic heterogeneity.
We performed drug prediction and validation through molecular docking and molecular dynamics analysis to identify candidate drugs that could promote or inhibit RNA expression. Our findings revealed that could serve as a biomarker in thyroid carcinoma, play a role with different FRGs in various cell types, and mediate different ligand-receptor pathways for cell-cell communication.
Overall, our study highlights the potential of as a novel biomarker for predicting prognosis and immunotherapeutic efficacy in thyroid carcinoma and suggests its potential for developing novel antitumor drugs or improving immunotherapy.
(铁硫簇组装蛋白1)参与铁硫(Fe-S)簇的组装,铁硫簇对于电子传递和酶活性至关重要。一些研究表明,其可能通过与铁死亡相关基因(FRGs)和肿瘤免疫微环境(TME)相互作用参与肿瘤进展。然而,尚未对其在FRGs和TME中的作用,或其对不同癌症类型预后和免疫治疗反应的预测价值进行系统分析。
在本研究中,我们通过来自TCGA和CPTAC数据库的数据及临床信息,分析了多种肿瘤组织中(铁硫簇组装蛋白1)的RNA、CNV、甲基化和蛋白质的表达及预后情况。我们对(铁硫簇组装蛋白1)与FRGs、免疫相关基因(包括免疫调节基因和免疫检查点基因)、免疫细胞浸润、免疫浸润评分、肿瘤干性和基因组异质性之间的相关性进行了全面分析。
我们通过分子对接和分子动力学分析进行药物预测和验证,以确定可促进或抑制(铁硫簇组装蛋白1)RNA表达的候选药物。我们的研究结果表明,(铁硫簇组装蛋白1)可作为甲状腺癌的生物标志物,在不同细胞类型中与不同的FRGs发挥作用,并介导不同的配体-受体途径进行细胞间通讯。
总体而言,我们的研究突出了(铁硫簇组装蛋白1)作为预测甲状腺癌预后和免疫治疗疗效的新型生物标志物的潜力,并表明其在开发新型抗肿瘤药物或改善免疫治疗方面的潜力。